Cost-effectiveness of antiretroviral therapy for prevention

Current HIV Research

Volumn 9, Issue 6, 2011, Pages 405-415

  Kahn, James G ^a   Marseille, Elliot A ^b   Bennett, Rod ^c   Williams, Brian G ^d   Granich, Reuben ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Health Strategies International   (United States)

^c Independent Consultant ^*  (United Kingdom)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antiretroviral therapy; cost analysis; cost effectiveness; economics; HIV prevention

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR;

ACUTE PHASE RESPONSE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; EPIDEMIC; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MORBIDITY; POPULATION MODEL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEXUAL TRANSMISSION; TUBERCULOSIS;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 80055081690     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798038542     Document Type: Review

References (47)

1. Potts M, Halperin DT, Kirby D, et al. Public health. Reassessing HIV prevention. Science 2008; 320(5877): 749-50.
2. The MSF Campaign for Access to Essential Medicines. Untangling the web of antiretroviral price reductions. Médecins Sans Frontières, Geneva 2011. Available at: http://www.msf.org.ar/upload/notic ias/AIDS_report_UTW14_ENG_2011_FINAL.pdf. Accessed Aug-ust 12, 2011.
3. WHO, UNAIDS, UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. WHO, Geneva 2010. Available at: www.who. int/hiv/pub/2010progressreport/en/. Accessed August 11, 2011.
4. Hirnschall G, Schwartländer B. Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011; 378 (9787): 209-11.
5. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23(11): 1397-404.
6. Donnell D, Baeten JM, Kiarie J, et al. Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375(9731): 2092-8.
7. Cohen MS CY, McCauley M, Gamble T, et al. The HPTN 052 Study Team. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011; Jul 18 [Epub ahead of print].
8. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373(9657): 48-57.
9. Leeper SC, Reddi A. United States global health policy: HIV/AIDS, maternal and child health, and The President's Emergency Plan for AIDS Relief (PEPFAR). AIDS 2010; 24(14): 2145-9.
10. Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. WHO Guide to Cost-Effectiveness Analysis. WHO, Geneva 2003; p. 245. Available at: www.who.int/choice/publications/p_2003_generalis ed_cea.pdf. Accessed August 11, 2011.
11. Badri M, Maartens G, Mandalia S, et al. Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa. PLoS Med 2005; 3(1): e4.
12. Cleary S, Boulle A, McIntyre D, Coetzee D. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Cape Town: Médecins Sans Frontières, Health Systems Trust, University of Capetown; 2004.
13. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Br Med J 2005; 331: 1431-7.
14. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006; 355(11): 1141-53.
15. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007; 21:1333-40.
16. Walensky RP, Wood R, Ciaranello AL, et al. Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource- Limited Settings: A Model-Based Analysis. PLoS Med. 2010; 7(12): e1000382.
17. Marseille E, Kahn JG, Pitter C, et al. The Cost-Effectiveness of Home- Based Provision of Antiretroviral Therapy in Rural Uganda. Appl Health Econ Health Policy 2009; 7(4): 229-43.
18. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/ AIDS interventions in Africa: A systematic review of the evidence. Lancet 2002; 359: 1635-43.
19. Galárraga O, Colchero A, Wamai RG, Bertozzi SM. HIV prevention cost-effectiveness: a systematic review. BMC Public Health 2009; 9(Suppl 1): S5.
20. Demaria LM, Bautista-Arrendondo SA, Galárraga O. What Works to Prevent and Treat AIDS: A review of cost-effectiveness literature with a long-term perspective. aids2031 Financing Working Group, Results for Development Institute, 2009; Working Paper No. 27.
21. Johri M, Ako-Arrey D. The cost-effectiveness of preventing mother-to- child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc 2011; 9: 3.
22. Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 2006; 3(12): e517.
23. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342(13): 921-9.
24. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29(3): 275-83.
25. Donnell D, Baeten JM, Kiarie J, et al. Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010: 375(9731): 2092-8.
26. Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 2010; 24(8): 1177-83.
27. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40(1): 96-101.
28. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20(1): 85-92.
29. Wood E, Kerr T, Marshall B, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Br Med J 2009; 338: b1649.
30. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376(9740): 532-9.
31. Fang C, Hsu H, Twu S, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190: 879-85.
32. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5(6): e11068.
33. Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008; 197(9): 1324-32.
34. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368(9534): 531-6.
35. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2(8): 487-93.
36. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327(5966): 697-701.
37. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50(1): 98-105.
38. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2009; 373(9657): 9-11.
39. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 Transmission per Coital Act, by Stage of HIV-1 Infection, in Rakai, Uganda. J Infect Dis 2005; 191(9): 1403-9.
40. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 Transmission, by Stage of Infection. J Infect Dis 2008; 198(5): 687-93.
41. th Conference on Retroviruses and Opportunistic Infections, 2006 Feb. 5-8; Denver, Colorado. Abstract 913.
42. Garnett G, Eaton J, Hallett T, et al. The Future of the HIV Pandemic. Aids2031. 2009.
43. HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24(1): 123-37.
44. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378(9787): 256-68.
45. Johnston KM, Levy AR, Lima VD, et al. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010; 24(12): 1929-35.
46. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Annals Intern Med 2010; 153: 778-89.
47. Long EF, Brandeau ML, Galvin CM, et al. Effectiveness and cost- effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 2006, 20: 2207-15.